Library of Economics and Liberty masthead logo
 
Search EconLog
Recent Entries
Entries by author
Bryan Caplan
David Henderson
Arnold Kling
Browse Archives
by date
by author
by category
Subscribe
About EconLog
Frequently Asked Questions
EconLog FAQ
Econlib Resources
About Econlib
Contact Econlib
Quote of the Day
Birthdays & Commemorations
Frequently Asked Questions
Get Econlib Newsletter
Subscribe to EconLog
XML (Full articles)
RDF (Excerpts)
Feedburner (One-click subscriptions)

Subscribe by author
Bryan Caplan
David Henderson
Arnold Kling  
More
FAQ (Instructions and more options)
Share



Return to top
Articles EconLog EconTalk Books Encyclopedia Guides Search
David R. Henderson  
PERMANENT LINK | JANUARY 3, 2010

Consumer Surplus from Cancer Drugs

David Henderson
PRINT
Share SHARE
Another Masonomist Likes the N... FP2P Watch...
Between 1988 and 2000, life expectancy for cancer patients increased by roughly four years, and the average willingness-to-pay for these survival gains was roughly $322,000. Improvements in cancer survival during this period created 23 million additional life-years and roughly $1.9 trillion of additional social value, implying that the average life-year was worth approximately $82,000 to its recipient. Health care providers and pharmaceutical companies appropriated 5-19% of this total, with the rest accruing to patients. The share of value flowing to patients has been rising over time.

This is from Eric C. Sun, Anupam B. Jena, Darius N. Lakdawalla, Carolina M. Reyes, Tomas J. Philipson, and Dana P. Goldman, "An Economic Evaluation of the War on Cancer," NBER Working Paper No. 15574, December 2009.

I couldn't find an ungated version.

H/T to Free Market Mojo.


Comments and Sharing


CATEGORIES: Economics of Health Care


   

COMMENTS (4 to date)
michael writes:

It is worth noting that most college students reading this blog have access to NBER working papers through their library websites.

Posted January 3, 2010 4:11 AM
Matt writes:

Does "willingness-to-pay" mean that's what they paid out of pocket?

Posted January 3, 2010 2:20 PM
Blackadder writes:

Between 1988 and 2000, life expectancy for cancer patients increased by roughly four years

How much of that is simply a statistical artifact of earlier detection?

Posted January 4, 2010 8:42 AM
Dan Weber writes:

I really have to repeat Blackadder's question. It's one of the biggest problems with people who think that "early detection saves lives." Well, it might, but most analyses along these lines fail basic statistical corrections.

There is also the Will Rogers effect.

As someone who tries to keep up-to-date on medical research and oncology (albeit as an amateur), a 4 year extension in cancer survival would be amazing. Especially because "cancer" is a cover-all word for a huge category of different conditions.

Posted January 4, 2010 11:26 AM
Comments for this entry have been closed
Return to top
Copyright © 2003-2011
Liberty Fund, Inc.
All Rights Reserved
Blogging software: Powered by Movable Type 4.2.1.
Pictures courtesy of the authors.
All opinions expressed on EconLog reflect those of the author or individual commenters, and do not necessarily represent the views or positions of the Library of Economics and Liberty (Econlib) website or its owner, Liberty Fund, Inc.

Liberty Fund logo, amagi symbol
The cuneiform inscription in the Liberty Fund logo is the earliest-known written appearance of the word "freedom" (amagi), or "liberty." It is taken from a clay document written about 2300 B.C. in the Sumerian city-state of Lagash.
spacer gif